These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 6460972)

  • 21. Pharmacokinetics of azlocillin in healthy subjects.
    Leroy A; Humbert G; Fillastre JP
    Scand J Infect Dis Suppl; 1981; 29():49-54. PubMed ID: 6947405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacokinetic study of guanfacine in patients with renal insufficiency and in patients under chronic dialysis (author's transl)].
    Kiechel JR; Lavene D; Gurret M; Coustenoble J; Petrover M; Godin M; Fillastre JP
    Nephrologie; 1980; 1(2):73-81. PubMed ID: 7029332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the pharmacokinetics of latamoxef in normal and impaired renal function.
    Höffler D; Koeppe P; Moecke D
    Arzneimittelforschung; 1984; 34(3):317-20. PubMed ID: 6539614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Tissue concentrations of mezlocillin in prostate adenomas following intravenous bolus injections and continuous infusions].
    Naber K; Adam D
    Fortschr Med; 1983 Nov; 101(41):1862-8. PubMed ID: 6197351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of the new broad spectrum penicillin CP-33994-2.
    Bergan T; Brodwall EK; Orjavik O
    Arzneimittelforschung; 1980; 30(7):1144-7. PubMed ID: 7191297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacokinetics of azlocillin in impaired renal function and haemodialysis (author's transl)].
    Schurig R; Kampf D; Becker H; Förster D
    Arzneimittelforschung; 1979; 29(12a):1944-8. PubMed ID: 543896
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison between the pharmacokinetic properties of mezlocillin when given intravenously as a bolus injection or as an infusion.
    Ohlsson H; Bergan T
    Arzneimittelforschung; 1979; 29(12a):1958-9. PubMed ID: 543900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
    Periclou A; Ventura D; Rao N; Abramowitz W
    Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Serum concentration and kinetics after i.v.-infusion of 3 g lincomycin (author's transl)].
    Adam D; Pätzold J
    Arzneimittelforschung; 1979; 29(1):130-4. PubMed ID: 582106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of anakinra in subjects with different levels of renal function.
    Yang BB; Baughman S; Sullivan JT
    Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacokinetic studies on broad spectrum antibiotic combinations of penicillin and oxacillin in normal volunteers (author's transl)].
    Adam D; Bauer W; Seitz B; Voigt I
    Arzneimittelforschung; 1979; 29(11):1769-804. PubMed ID: 543889
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mezlocillin pharmacokinetics in renal impairment.
    Aronoff GR; Sloan RS; Luft FC; Nelson RL; Maxwell DR; Kleit SA
    Clin Pharmacol Ther; 1980 Oct; 28(4):523-8. PubMed ID: 6447570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis.
    Eriksson T; Höglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA
    J Pharm Pharmacol; 2003 Dec; 55(12):1701-6. PubMed ID: 14738599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Experimental and clinical study of the biliary elimination of mezlocillin (author's transl)].
    Brogard JM; Kopferschmitt J; Dorner M; Lavillaureix J
    Pathol Biol (Paris); 1981 Sep; 29(7):405-10. PubMed ID: 6457274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacokinetics and dosage of mezlocillin administered by intravenous infusion].
    Modr Z; Dvorácek K; Janků I; Krebs V
    Infection; 1982; 10 Suppl 3():S191-5. PubMed ID: 6218111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetics of mezlocillin and carbenicillin.
    Pancoast SJ; Neu HC
    Clin Pharmacol Ther; 1978 Jul; 24(1):108-16. PubMed ID: 657712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pharmacokinetics of azlocillin in chronic renal failure and hemodialysis patients].
    Fillastre JP; Humbert G; Leroy A; Godin M
    Presse Med; 1984 Mar; 13(13):797-801. PubMed ID: 6231597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mezlocillin disposition in chronic hemodialysis patients.
    Janicke DM; Mangione A; Schultz RW; Jusko WJ
    Antimicrob Agents Chemother; 1981 Nov; 20(5):590-4. PubMed ID: 6459760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.